Amgen (NASDAQ:AMGN) has submitted a marketing application to the FDA seeking approval of AMG 798, a biosimilar to Roche’s (OTCQX:RHHBY) Rituxan (rituximab).
The company is collaborating with Allergan (NYSE:AGN) on four biosimilars, two of which are approved in the U.S. It has primary responsibility for development, manufacturing and initial commercialization.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.